When to get the joint checked before treatment

When to seek care without waiting

Seek care that day for joint heat and swelling with fever. A changed joint shape after a fall also needs prompt care. Get help if the leg can't hold you. A locked joint needs an exam too. Don't watch these problems at home.

New weakness or numbness can also be urgent. Get immediate care for bladder or bowel trouble with back symptoms. Call when soreness becomes much worse in a short time. Unplanned weight loss or repeated lost sleep also deserves an exam.

After a joint procedure, call for spreading redness or warmth. Fever or worsening soreness also needs a prompt call.

What to tell the person examining you

Bring a full medicine list. Point out blood thinners, diabetes, recent infection and past reactions. Don't stop medicine unless the doctor who ordered it agrees.

Say when the soreness began and show the motion that hurts. Bring earlier X-rays and physical therapy notes when you have them. Those records show which exams and exercises were already done.

At QC Kinetix, medical providers examine joints and discuss regenerative treatment options, clinic procedures prepared from your blood. That visit can't replace urgent care for the warning signs above.

What to ask about a good fit

Ask what is causing the soreness and how far it has gone. Then ask why the suggested treatment fits the exam. Results from knees don't always apply to hips or shoulders.

Name one task you want to make easier. It could be a walk, a chore or a night of sleep. Ask when you may notice relief. Decide how much change would make the cost worthwhile.

The catch is damage that is already far along. It can leave you with fewer choices besides surgery. If surgery was advised, ask whether a blood-based shot would only postpone needed care. You'll then know whether waiting has a cost.

Sources

1. The AAOS third-edition clinical practice guideline on non-arthroplasty management of knee osteoarthritis contains 29 recommendations and explicitly highlights intra-articular corticosteroid, hyaluronic acid AND platelet-rich plasma as the areas where better research is still needed - including osteoarthritis characterisation, subgroup and severity stratification, control for bias, and cost-effectiveness analysis.

   Brophy RH, Fillingham YA. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

2. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

4. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

5. A meta-analysis of 11 RCTs (730 patients) with lateral epicondylitis found the timing reverses the answer: corticosteroid was significantly BETTER than PRP in the short term (under 2 months: VAS mean difference 0.93 favouring steroid; DASH 10.23 favouring steroid), the two did not differ at 2-6 months, and PRP was significantly better at 6 months or more (VAS -2.18; DASH -8.13; Mayo Elbow +16.53).

   Xu Y, et al. — Platelet-Rich Plasma Has Better Results for Long-term Functional Improvement and Pain Relief for Lateral Epicondylitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. American Journal of Sports Medicine, 2024. DOI: 10.1177/03635465231213087.

6. A meta-analysis of 24 RCTs (1,653 participants) with plantar fasciitis found PRP produced significantly better VAS pain than corticosteroid at 3 and 6 months but not at 1 month or 12 months, and better AOFAS function scores at 3, 6 and 12 months. Plantar fascia thickness did not differ significantly at any time point.

   Zuo A, et al. — Platelet-Rich Plasma Versus Corticosteroids in the Treatment of Plantar Fasciitis: A Systematic Review and Meta-analysis.. American Journal of Physical Medicine & Rehabilitation, 2025. DOI: 10.1097/PHM.0000000000002677.